Re: The Immune Response Corporation Announces Multiple Sclerosis Phase II Clinical Trial

[Guest guest]

This sounds a lot like some of the same things LDN does.

http://www.imnr.com/news/2004/2004APR06.htm

April 6, 2004

The Immune Response Corporation Announces Multiple Sclerosis Phase II Clinical Trial Under New GrantClinical Results Accepted for Presentation at Upcoming AAN Meeting

Carlsbad, California – April 6, 2004 -- The Immune Response Corporation (NASDAQ: IMNR), a biopharmaceutical company developing immune-based therapies (IBT) for HIV and select other diseases, announced today the awarding of an Immune Tolerance Network grant which will provide the funding for continued research on NeuroVaxTM, an experimental therapy to treat multiple sclerosis (MS). NeuroVaxTM is a T-cell receptor (TCR) peptide vaccine designed to treat MS through an immunological mechanism of action. Clinical research from a recently completed Phase II study leading to this award has been accepted for presentation at the 54th annual meeting of the American Academy of Neurology (AAN) to be held in late April in San Francisco, CA.

“The grant will allow us to continue to develop NeuroVaxTM without diverting resources from our HIV clinical program,” said N. Bonfiglio Ph.D, Chief Executive Officer of The Immune Response Corporation. “The technology behind NeuroVaxTM adds depth to our pipeline and provides opportunities to partner these products in the future. We are delighted that our abstract on the data leading to this award was accepted for an oral presentation at the prestigious AAN meeting. We believe our immunologic approach to the treatment of MS offers another treatment protocol that could be used as part of the fight against this terribly debilitating disease.”

NeuroVaxTM activity is thought to be through its ability to stimulate regulatory T-cells, which are believed to be responsible for down-regulating the pathogenic activated T-cells over-expressed and provoking the autoimmune responses in patients afflicted with MS. This activity is another example of how immune-based therapies pioneered by The Immune Response Corporation’s co-founder, Dr. Jonas Salk, may potentially provide new mechanisms for fighting difficult disease conditions. NeuroVaxTM shows potential to be used as monotherapy as well as in combination with currently approved treatments.

The grant, awarded by the Immune Tolerance Network (ITN), an international research consortium, to Oregon Health Sciences University (OHSU) is being used to fund the open-label trial of NeuroVaxTM at OHSU under an approved IND held by The Immune Response Corporation. The grant was awarded based partially on a recently completed Phase II study at OHSU that investigated the immunogenicity of NeuroVaxTM given with and without an adjuvant. Under the grant, the ITN will provide funding and technical support for additional biological assays studies to be performed as part of the trial that will investigate the mechanisms of action of NeuroVaxTM and seek to establish additional endpoints for therapeutic efficacy.

About the Immune Tolerance Network

The Immune Tolerance Network is an international research consortium that aims to accelerate the clinical development of immune tolerance therapies for use in transplantation, autoimmune diseases and allergy and asthma. Headquartered at the University of California San Francisco, the ITN is comprised of over 80 leading physicians and scientists from over 40 institutions in 9 countries world-wide. The ITN is sponsored by the National Institute of Allergy and Infectious Diseases, with additional funds provided by the National Institute of Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes Research Foundation. Additional information on the Immune Tolerance Network may be found at www.immunetolerance.org.

About The Immune Response Corporation

The Immune Response Corporation (NASDAQ: IMNR) is developing immune-based therapies (IBT) for HIV and select other diseases. The Company’s HIV products are based on its patented whole-killed virus technology, co-invented by Company founder, Dr. Jonas Salk, to stimulate broad and potent HIV immune responses. REMUNE®, currently in Phase II, is being developed as a first line treatment for people with early-stage HIV. The Company has initiated development of a new IBT, IR103, which incorporates a state-of-the-art immune system booster.

The Immune Response Corporation is also developing an IBT for Multiple Sclerosis (MS), NeuroVaxTM which is currently in Phase II and has shown potential therapeutic value for this difficult-to-treat disease.Please visit The Immune Response Corporation on the World Wide Web at www.imnr.comThis news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE® or NeuroVaxTM, the uncertainty of successful completion of any such clinical trials, whether REMUNE® or NeuroVaxTM, will be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE® or NeuroVaxTM, in preclinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2003. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

NeuroVaxTM is a trademark of The Immune Response Corporation. REMUNE® is a registered trademark of The Immune Response Corporation.